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Summary 
The incidence of melanoma has risen dramatically during the past three decades, yet 
there has been little improvement in effective treatments for this intractable and 
aggressive disease. Melanoma tumours are notoriously resistant to apoptosis, a cell 
suicide program that is activated by most cancer therapies. This thesis explores the role 
of the melanoma susceptibility gene product p14ARF in promoting cell cycle arrest and 
apoptosis, in order to resolve the impact of this tumour suppressor in melanomagenesis 
and melanoma susceptibility. 
 
The p14ARF tumour suppressor gene is mutated in almost half of all cancers, and 
germline mutations in p14ARF confer a greatly increased risk of developing melanoma. 
The primary function of p14ARF is to relay oncogenic signals to p53, a central 
regulator of cellular response to stress. There is conflicting evidence regarding the role 
of p14ARF in promoting apoptosis. Much of the current evidence is based on murine 
studies, which may not translate accurately to humans due to important differences in 
animal physiology and the primary sequence and functions of the mouse and human 
ARF proteins. Furthermore, results from previous studies are often confounded by 
supra-physiological expression of p14ARF, and are complicated by the fact that 
p14ARF shares its genomic sequence with the p16INK4a tumour suppressor gene. 
 
This study demonstrates that p14ARF expression in human cancer and primary cell 
lines promotes rapid p53-dependent cell cycle arrest, rather than apoptosis. As p14ARF 
expression did not induce apoptosis, we investigated if p14ARF could modulate the 
sensitivity of a cell to apoptosis induced by cytotoxic agents. Using a p14ARF-
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inducible U2OS osteosarcoma cell line model, we examined the impact of p14ARF 
expression on the apoptotic response of the cell to a panel of thirteen cytotoxic agents. 
p14ARF expression increased apoptosis caused by a sub-set of agents, including 
trichostatin A, sodium butyrate, DRB, Adriamycin and UVB radiation.  
 
p14ARF-mediated chemosensitivity was p53- and caspase-dependent, and involved the 
loss of mitochondrial potential. While loss of mitochondrial potential was dependent on 
p53, it was not blocked by caspase inhibition, demonstrating that caspases play a role 
downstream of mitochondrial depolarisation. Inhibition of individual components of the 
apoptotic program showed that p14ARF-mediated chemosensitivity was not strictly 
dependent on the pro-apoptotic Bax or Fas proteins.  
 
We also investigated whether p14ARF could sensitise melanoma to chemotherapeutics 
in vivo. We investigated the expression level of p14ARF, p16INK4a and MITFm and 
mutation status of B-RAF, N-RAS and PTEN in melanomas from 30 patients that had 
undergone isolated limb infusion - a palliative therapeutic strategy that results in much 
higher response rates than systemic treatment. Expression of p14ARF did not predict 
response to the drugs actinomycin D and melphalan . Instead, high expression of 
p16INK4a and presence of activating N-RAS mutation were independent predictors of 
response to high doses of these chemotherapeutic drugs. 
 
This work suggests that p14ARF analogues may be beneficial adjuncts in cancer 
therapy, but are unlikely to be effective as single agents. Additionally, p14ARF 
mimetics will only be effective in tumours with intact p53 signalling. Melanomas 
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frequently carry functional p53, and may be susceptible to this mode of treatment 
providing the apoptotic pathway downstream of p53 is intact or can be restored. 
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1. Literature review 
1.1 Cancer and Melanoma 
Cancer is the second largest cause of death in Australia. The rate of newly diagnosed 
cancer continues to increase with the increasing average age of the population (up 26% 
from 1993 to 2003) (AIHW and AACR, 2007); however on an age adjusted basis, 
cancer rates have decreased 0.7% over this period. Despite overall reduced age adjusted 
incidence and mortality rates for cancer, rates of melanoma continue to rise. In the UK, 
age-standardised melanoma rates have increased almost five-fold in males, and over 
three-fold in females since 1975 (Lens and Dawes, 2004; www.cancerresearchuk.org, 
2007). Rates have also increased in the US - from 1973 to 1997, the age adjusted 
melanoma rate jumped from 6.7 to 19.3 per 100000 in men, and from 5.9 to 13.8 in 
women (Jemal et al., 2001).  
 
In Australia, the number of new melanoma cases rose by 40.8% between 1983 and 
2003, and the age-standardised rate increased 13.9% in the same period to 46.9/100000 
(AIHW and AACR, 2007). During this period the number of deaths from melanoma 
also increased by 34.3% to 1146, with age-standardised mortality rates increasing 
marginally from 5.3 to 5.6 per 100000. Melanoma death rates appear to have plateaued 
in the last decade, due to earlier detection rather than improved therapies (Howe et al., 
2001; Miller and Mihm, 2006).  
 
The increased rate of melanoma development in the last decade is the result of increased 
exposure to ultraviolet (UV) radiation (Armstrong and Kricker, 2001). This has been 
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caused by changes in behaviour and attitude to sun exposure, and to a lesser extent, by 
ozone depletion (Beddingfield, 2003; Burton and Armstrong, 1994). Australians 
younger than 35 years of age have grown up with effective sun education programs 
such as the Cancer Council’s “Slip, Slop, Slap” campaign and have adopted safer sun 
exposure behaviour. This has resulted in reduced melanoma rates in this cohort (Coory 
et al., 2006; Marks, 1999). However, the reduced melanoma risk in this younger age 
group will not have a large impact on overall melanoma rates until they are older, and it 
is predicted that overall rates of melanoma will continue to increase for at least another 
20 years, albeit more slowly (McDermid et al., 2005).  
 
1.1.1 Melanoma Prognosis 
Increasing rates of melanoma are of particular concern because effective therapies are 
limited for metastatic melanoma. Although stage I melanoma (no signs of cancer spread 
and less than 2mm thick) has a 95% cure rate by surgical excision, patients presenting 
with metastatic melanoma have five year survival rates of 65% for patients with 
regional melanoma, and 15% for patients with distant melanoma (Jemal et al., 2004). 
Less than 10% of patients with visceral involvement survive two years (Balch et al., 
2001a). 
 
Therapeutic options for patients with metastatic melanoma have remained relatively 
unchanged for the past three decades and dacarbazine remains the best systemic 
treatment (Eggermont and Kirkwood, 2004). Overall response rates to dacarbazine are 
less than 15% (Avril et al., 2004; Middleton et al., 2000; Millward et al., 2004) 
although certain patients have highly sensitive tumours and rare complete remissions 
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are sustained (Coates and Segelov, 1994). While much work is being done on immune 
and bio-chemotherapies and adjuvants, these have yet to yield significant therapeutic 
improvement (reviewed in (Eggermont and Kirkwood, 2004; Thompson et al., 2005)) 
 
1.1.2 Melanoma and apoptosis 
The source of melanoma’s recalcitrance to treatment lies in its resistance to apoptosis 
(programmed cell death) (reviewed in (Soengas and Lowe, 2003)). Melanoma arises 
from melanocytes, cells of neural crest origin that are responsible for the generation of 
melanin - a pigment that is distributed to surrounding cells and protects the skin from 
sun damage. The role of the melanocyte in protecting the skin requires that they are 
intrinsically resistant to the damaging effects of UV radiation, and as a result 
melanocytes are inherently resistant to apoptosis. For example, whereas most cells 
exposed to UV radiation undergo cell death or proliferative arrest, melanocytes are 
stimulated to grow by α-melanocyte-stimulating hormone that is produced by 
melanocytes and surrounding keratinocytes (Chakraborty et al., 1996; Schauer et al., 
1994). The intrinsic resistance of melanocytes to apoptosis is largely attributed to high 
expression levels of anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members. During 
melanomagenesis, melanoma cells acquire mutations that fortify these defences against 
death, while driving growth and metastatic potential (Bush and Li, 2003; Soengas and 
Lowe, 2003).  
 
Over 80% of melanomas gain growth signals from oncogenic activation of the mitogen 
activated protein kinase (MAP Kinase) pathway members B-RAF (V-raf murine 
sarcoma viral oncogene homolog B1) and N-RAS (Neuroblastoma RAS viral (v-ras) 
4 
oncogene homolog), or the receptor tyrosine kinase c-Kit. Intriguingly, these oncogenes 
are altered with different frequencies in different types of melanoma, suggesting 
different pathways of melanomagenesis (Table 1.1). For example, c-Kit alterations 
occur in 30-50% of mucosal and acral melanomas, and in melanomas arising from 
chronically sun damaged skin, but are rare in melanomas arising from intermittently sun 
exposed skin (Curtin et al., 2006). In contrast, B-RAF mutations occur in up to 70% of 
benign naevi and cutaneous melanoma, while they occur in less than 20% of acral or 
mucosal melanomas (Kumar et al., 2003a; Kumar et al., 2004; Sasaki et al., 2004). 
Spitz naevi and blue melanoma - both rare melanocytic neoplasms - have a very low 
occurrence of B-RAF and N-RAS mutations and have not yet been thoroughly 
investigated for c-Kit alterations (Indsto et al., 2007; Saldanha et al., 2004). 
 
Table 1.1 Prevalence of activating alterations of c-Kit, B-RAF and N-RAS in melanoma 
by subtype. 
Gene Naevi Non-CSD CSD Mucosal Acral Spitz Blue 
B-RAF 30-70% 50-60% 50-60% <10% 10-20% <12% 0% 
N-RAS 10-20% 10-25% 10-25% 10-20% 10-20% <6% 0% 
c-Kit <10% 0% 30% 40% 35-50% ND ND 
CSD, chronic sun damage, ND, not determined 
References used in table: (Curtin et al., 2006; Curtin et al., 2005; Davies et al., 2002; Gorden et al., 2003; 
Indsto et al., 2007; Janku et al., 2005; Kumar et al., 2003a; Kumar et al., 2003b; Kumar et al., 2004; 
Maldonado et al., 2003; Ohashi et al., 1996; Omholt et al., 2002; Omholt et al., 2003; Saldanha et al., 
2006; Sasaki et al., 2004; Ugurel et al., 2007; Yazdi et al., 2003) 
 
The progression from melanocyte to metastatic melanoma involves the transition 
through a number of stages, usually involving progression from naevi to dysplastic 
naevi, to primary melanoma spreading superficially and/or vertically, then finally to 
metastatic melanoma (Miller and Mihm, 2006). In an attempt to understand melanoma 
progression and provide effective prognostic information, studies have investigated 
genetic changes that occur during these different stages to determine the suite of genes 
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that are altered during progression. The Bcl-2 family of proteins, which are critical in 
transmitting apoptotic signals, are frequently altered during melanoma progression and 
play a central role in the resistance of melanoma tumours to apoptosis (Zhuang et al., 
2007). This family contains many pro- and anti-apoptotic proteins and their functions 
will be reviewed in more depth later in this chapter.  
 
Unexpectedly, expression of the anti-apoptotic Bcl-2 protein is often decreased in 
melanomas and expression of pro-apoptotic Bax and Bak proteins is retained or 
increased (Table 1.2). Although this seems counter-intuitive, melanoma tumours 
frequently over-express other anti-apoptotic members of the Bcl-2 family - in particular 
Mcl-1 and Bcl-xL. Thus melanomas do not require Bcl-2 and can overcome the pro-
apoptotic signalling of Bax and Bak (Table 1.2). Additionally, the down-regulations of 
other pro-apoptotic Bcl-2 family members (such as PUMA) negate the requirement for 
Bak and Bax reduction. 
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Table 1.2 Percentage of naevi, primary and metastatic melanomas expressing high 
levels of various Bcl-2 family proteins. 
Bcl-2 family 
members 
Melanocytes Naevi Primary Metastatic Association with 
Progression 
Anti-apoptotic      
Bcl-2 43 46-100 50-60 30-80 Mostly decreased1 
Bcl-xL 30-60 30-80 80-100 80-100 Increased 
Mcl-1 03 70-80 60-90 80-100 Increased 
Survivin2 0 100 ND 70-100 Increased 
XIAP2 03 0 25-75 75 Increased 
      
Pro-Apoptotic      
Bax 100 100 75 70-100 Increased 
Bak 100 ND 85 85 Steady or increased 
PUMA 100 100 60 30 Decreased 
1The majority of reports indicate that decreased Bcl-2 expression is associated with melanoma 
progression 
2Survivin and XIAP are inhibitor of apoptosis proteins (IAPs), not Bcl-2 members.  
3Melanocytes express low levels of Mcl-1 and XIAP 
ND, Not determined 
References used in table: (Divito et al., 2004; Emanuel et al., 2008; Fecker et al., 2006; Gradilone et al., 
2003; Grossman et al., 1999; Karst et al., 2005; Leiter et al., 2000; Selzer et al., 1998; Tang et al., 1998; 
Zhuang et al., 2007) 
 
Many other proteins important for triggering apoptosis are also disabled in melanoma. 
The initiators of apoptosis located at the cell surface are often disabled - fibroblast-
associated receptor (Fas) is mutated in 7% of metastatic melanomas (Shin et al., 1999) 
and wild-type Fas is generally expressed at low levels in melanomas due to promoter 
methylation (Bullani et al., 2002). Metastatic melanoma is frequently resistant to 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), with 35-45% of 
tumours displaying decreased expression of the receptors TRAIL-R1 and TRAIL-R2 
(Zhuang et al., 2006). The apoptotic protease activating factor-1 (APAF-1), a 
downstream component of the apoptosis cascade, is critical for the activation of caspase 
9, and may be decreased by loss of heterozygosity in up to 40% of melanomas (Dai et 
al., 2004; Soengas et al., 2001), although this figure may be much lower (Allen et al., 
2005; Peltenburg et al., 2005). Additional protection from apoptosis occurs via the 
direct inhibition of activated caspases by the inhibitor of apoptosis proteins (IAPs). 
7 
IAPs include survivin and XIAP, and are increased in over 70% of melanomas 
(Emanuel et al., 2008; Gradilone et al., 2003; Grossman et al., 1999). 
 
One of the central components of a cell’s response to stress is the tumour suppressor 
protein and “guardian of the genome”, p53, which is mutated in over half of all cancers 
(Lane, 1992). Given that melanoma is an aggressive and intractable disease, it is 
surprising that fewer than 25% of melanoma tumours disable p53 (Albino et al., 1994; 
Florenes et al., 1994; Gwosdz et al., 2006; Sparrow et al., 1995). Transfection of p53 
reporter plasmids into melanoma cells indicates that the endogenous p53 is functional 
and transcriptionally active (Kichina et al., 2003). The low rate of p53-inactivation in 
melanomas suggests that the p53-cell cycle regulatory pathway is inactivated via 
alternative means in this cancer. A recent report found that melanoma cells express 
various isoforms of p53 and some of these variants may inhibit the full-length protein 
(Avery-Kiejda et al., 2008). In mouse models of melanoma, disruption of the upstream 
p53 regulator ARF (Alternate Reading Frame) can functionally replace p53 loss during 
melanomagenesis, and melanomas arising in these animals carry wild-type p53 (Chin et 
al., 1997). 
 
The p14ARF and p16INK4a tumour suppressor proteins are of particular interest in 
melanoma. They are encoded by the INK4a/ARF locus on chromosome band 9p21 and 
are frequently inactivated in melanoma and other human cancers. Additionally, 
germline mutations affecting this locus confer a greatly increased risk of cutaneous 
melanoma (Sharpless and DePinho, 1999). The principal role of p14ARF is to promote 
the stabilisation of p53 by inhibiting the action of the p53-ubiquitin ligase human mdm2 
(HDM2) (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998). p53 promotes 
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cell cycle arrest and apoptosis, raising the possibility that p14ARF may also be pro-
apoptotic. However, the role of p14ARF in promoting apoptosis is equivocal as much of 
the evidence is conflicting and based on the murine homologue, p19ARF. In this thesis 
we investigated the role of human p14ARF in regulating cell cycle arrest and apoptosis. 
 
1.2 The ARF tumour suppressor 
1.2.1 The INK4a/ARF locus 
The Alternate Reading Frame (ARF) tumour suppressor protein (known as p14ARF in 
humans and p19ARF in mice) was originally identified as an alternative transcript of 
the INK4a/ARF tumour suppressor locus, a sequence that also encodes the p16INK4a 
inhibitor of cyclin dependent kinases 4 and 6 (Duro et al., 1995; Quelle et al., 1995). By 
virtue of unique first exons, the ARF and p16INK4a transcripts are translated in alternative 
reading frames and encode proteins bearing no homology. The p16INK4a gene utilises 
exons 1α, 2 and 3 and has a unique promoter. ARF utilises the upstream exon 1ß 
spliced to exons 2 and 3 and this transcript is translated in a different reading frame 
(Figure 1.1).  
 
The INK4a/ARF locus is second only to p53 in the frequency of its disruption in human 
cancer and is mutated, deleted or hyper-methylated in half of all tumours (Haber, 1997; 
Sharpless and DePinho, 1999; Sherr, 1996). While the frequent mutation of the 
INK4a/ARF sequence demonstrates its importance in cancer progression, the two 
products of this locus are especially relevant in melanoma, as germline mutations are 
inherited in 39% of melanoma-prone kindreds (Goldstein et al., 2006). 
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Figure 1.1 The structure of the INK4a/ARF locus 
 
 
1.2.2 INK4a/ARF mutations in melanoma kindreds 
Mutations in the INK4a/ARF locus confer increased risk of melanoma, pancreatic 
cancer and neural system tumours. Penetrance studies of families with mutations 
affecting this locus show that carriers have between 12-62% chance of developing 
melanoma before 50 years of age, rising to between 31-96% probability by 80 years of 
age (Bishop et al., 2002). There is a suggestion that mutations affecting both p14ARF 
and p16INK4a confer a higher risk of melanoma than p16INK4a-specific mutations 
(Berwick et al., 2006). Families with INK4a/ARF mutations also have a higher risk of 
pancreatic cancer, with one study demonstrating that carriers have 39 times the risk of 
developing this cancer compared to non-carriers (Borg et al., 2000). It is clear that 
p14ARF plays an important role in preventing pancreatic cancer, as the incidence of 
pancreatic cancer is higher in families carrying INK4a/ARF mutations that also affect 
the p14ARF amino acid sequence, compared to families carrying mutations that target 
p16INK4a exclusively (41% compared to 19% respectively) (Goldstein et al., 2007). 
 
10 
Inherited mutations involving the INK4a/ARF locus are most commonly missense 
mutations (65%), but also involve deletions (16%), insertions or duplications (7%), 
nonsense mutations (5%) and splice site variants (5%) (Goldstein et al., 2006; Goldstein 
et al., 2007). In melanoma prone families, p16INK4a appears to function as the primary 
melanoma suppressor as mutations specifically targeting p14ARF are uncommon, 
affecting only 2% of high risk melanoma families with INK4a/ARF mutations (Table 
1.3). Of the remaining families, 38% harbour mutations affecting the p16INK4a-specific 
exon 1α, and 60% carry alterations affecting exons 2 or 3, or the entire locus (Table 
1.3). It should be noted that 39% of the missense mutations affecting exons 2 and 3, 
specifically target p16INK4a and do not alter the p14ARF amino acid sequence. In 
contrast, exon 2 mutations that change the amino acid sequence of p14ARF but do not 
alter p16INK4a are rare (Goldstein et al., 2006; Goldstein et al., 2007). Mutations in both 
familial and sporadic melanoma cases are spread throughout the locus with 66% of 
mutations occurring in exon 2 (Figure 1.2). 
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Figure 1.2 The location of p16INK4a mutations 
The location of mutations affecting p16INK4a reported in somatic tumours (n=782) or in the germline of 
melanoma-prone kindreds (n=104). Exon 2 mutations may also affect the primary sequence of p14ARF 
(source https://biodesktop.uvm.edu/perl/p16). 
 
 
Table 1.3 Distribution of inherited INK4a/ARF mutations.  
Exon of 
Ink4a/ARF locus 
Frequency 
mutated 
Exon 1ß 2% 
Exon 1α 38% 
Exon 2 51% 
Exon 3 7% 
Deletion of locus 2% 
Data from 466 familial melanoma families (Goldstein et al., 2006). All exon 1ß mutations are either of 
deletions (3/7) or splice variants (4/7). 
 
While mutations in melanoma prone families target p16INK4a predominantly, the 
importance of p14ARF mutations in melanoma susceptibility should not be 
underestimated. 43% of point mutations affecting the exon 2 coding region of p14ARF 
are radical as judged by the Grantham algorithm - which predicts functional effects of 
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amino acid changes - while 71% were non-conservative (compared to 35% and 76% 
respectively for p16INK4a) (Goldstein et al., 2007). Additionally, a number of studies 
have identified knockout mutations that target exon 1ß in melanoma prone families, and 
these families are also more likely to develop neural system tumours (Goldstein et al., 
2007; Hewitt et al., 2002; Randerson-Moor et al., 2001; Rizos et al., 2001b). 
 
1.2.3 INK4a/ARF mutations in sporadic cancer 
The INK4a/ARF locus is disrupted in approximately half of all cancers by mutation, 
promoter methylation or deletion (Holland et al., 1999; Pollock et al., 1996; Sharpless 
and DePinho, 1999; Soufir et al., 1998; Walker et al., 1995). Although most 
INK4a/ARF mutations target p16INK4a, 52% of somatic INK4a/ARF alterations also 
affect the p14ARF amino acid sequence (Pollock et al., 1996) (Table 1.4). Alterations 
specifically affecting p14ARF are rare, but have been detected in human tumours and 
familial melanoma kindreds (Hewitt et al., 2002; Randerson-Moor et al., 2001; Rizos et 
al., 2001b). p53 is mutated in only 7% of cancers that have also lost p14ARF, and 
significantly, the loss of p14ARF almost always involves the concomitant loss of 
p16INK4a (Sharpless and DePinho, 1999). This suggests that ARF functions primarily via 
the p53 pathway, as the inactivation of these two tumour suppressors is usually 
mutually exclusive. It also supports data generated in human fibroblasts that the loss of 
p16INK4a provides a growth advantage in a p53-null background (Voorhoeve and Agami, 
2003). 
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Table 1.4 Proportion of mutations affecting p14ARF amino acid sequence in tumours 
with INK4a/ARF locus mutations.  
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p14ARF changed 52% 47% 48% 46% 62% 52% 58% 47% 48% 
 
Effect of all exon 2 mutations on p14ARF primary sequence 
Silent 22% 35% 30% 30% 19% 23% 8% 21% 22% 
Frameshift 9% 7% 4% 14% 11% 9% 12% 11% 7% 
Missense 55% 53% 57% 50% 49% 42% 55% 64% 63% 
Nonsense 3% 2% 4% 0% 4% 7% 4% 0% 0% 
Other 11% 4% 4% 7% 17% 19% 22% 4% 7% 
          
Tumours tested 781 79 33 67 124 84 81 47 44 
(Source: https://biodesktop.uvm.edu/perl/p16) 
 
1.2.4 The ARF tumour suppressor is a critical activator of the p53 pathway  
The ARF tumour suppressor protein suppresses aberrant cell growth in response to 
oncogene activation by inducing the p53-pathway (Figure 1.3). The p53 transcription 
factor is a central mediator of cell response to cytotoxic stress and oncogenic signalling. 
p53 is a labile protein that is rapidly stabilised by various cellular stress signals via post 
translational modification or inhibition of its negative regulators - most notably HDM2 
(for reviews see (Harris and Levine, 2005; Lavin and Gueven, 2006)). Once activated, 
tetramers of p53 bind specific DNA promoter sequences containing the sequence motif: 
RRRCWWGYYY-spacer of 0-21 nucleotides –RRRCWWGYYY (where R is a purine, 
W is A or T and Y is a pyrimidine) (Levine, 1997). p53 initiates a transcriptional 
program that can result in cell cycle arrest, senescence or apoptosis. p53 targets over a 
hundred genes for transcriptional activation or repression by promoter binding (Ho and 
Benchimol, 2003). The DNA binding domain of the p53 protein lies between amino 
acid residues 102 to 292 and 90% of cancer-associated missense mutations in p53 target 
14 
this region, demonstrating the importance of transactivation in the role of p53 as a 
tumour suppressor (Levine, 1997). 
 
Figure 1.3 The ARF tumour suppressor pathway 
HDM2 and ARF-BP1 ubiquitinate p53, leading to its degradation. p14ARF is induced by oncogenic 
signalling and inhibits HDM2 and ARF-BP1 activity, leading to the stabilisation of p53. p53 acts in a 
auto-regulatory feedback loop by repressing p14ARF transcription and activating HDM2 transcription. 
 
 
 
p14ARF is induced by various oncogenes, such as E2F1 and MYC (Drayton et al., 
2003; Parisi et al., 2002b). Once induced, ARF stabilisation of p53 is mediated through 
two ubiquitin ligases: HDM2, a RING finger oncoprotein, and ARF-BP1/Mule (ARF-
binding protein 1/Mcl-1 ubiquitin ligase E3), a HECT (homology to E6-AP C-terminus) 
containing protein (Figure 1.3) (Chen et al., 2005a; Pomerantz et al., 1998; Zhang et al., 
1998). Both HDM2 and ARF-BP1 act as specific E3 ubiquitin ligases for p53, are 
highly expressed in various types of tumours, and have the potential to impede the 
tumour suppressor functions of p53. p53 can act in a self-regulatory pathway by 
15 
promoting HDM2 transcription and repressing ARF transcription (Figure 1.3) (Stott et 
al., 1998). 
  
HDM2 is an E3 ubiquitin ligase that contains a C-terminal RING domain which is 
responsible for its ubiquitin ligase activity (Boddy et al., 1994; Fakharzadeh et al., 
1991). The transfer of ubiquitin onto target proteins is mediated by three separate 
enzymes: E1 (ubiquitin-activating enzyme); E2 (ubiquitin-conjugating enzyme); and E3 
(ubiquitin-protein ligase). The E3 protein binds the target and determines substrate 
specificity. HDM2 ubiquitinates p53 on at least six C-terminal lysine residues, leading 
to its nuclear export and degradation (Haupt et al., 1997; Honda et al., 1997; Lohrum et 
al., 2001; Nakamura et al., 2000). Initially it was thought that HDM2 could poly-
ubiquitinate p53 - which is required to target a protein for degradation by the 26S 
proteosome. However some in vitro studies have demonstrated that HDM2 mono-
ubiquitinates p53, and further ubiquitin chains are added by other, as yet undetermined 
proteins (Lai et al., 2001). One possibility is that HDM2 mono-ubiquitinates free p53, 
causing its nuclear export, while DNA bound p53 is initially mono-ubiquitinated by 
HDM2, then further poly-ubiquitinated by the p53 co-activator p300, leading to its 
proteosomal degradation in either the nucleus or cytoplasm (Grossman et al., 2003; 
Xirodimas et al., 2001; Yang et al., 2004). As well as promoting the nuclear export and 
degradation of p53, HDM2 can directly inhibit p53 transcription. Amino acids 19-108 
of HDM2 mediate binding to the N-terminal transactivation domain of p53 (Bottger et 
al., 1997), thereby concealing this domain from co-activators and transcriptional 
machinery and repressing p53 transactivation (Momand et al., 1992; Oliner et al., 
1993). 
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ARF associates with HDM2 to inhibit the ubiquitination, nuclear export and subsequent 
degradation of p53 (Tao and Levine, 1999; Zhang et al., 1998). It has been proposed 
that ARF physically sequesters HDM2 in nucleoli, thus relieving nucleoplasmic p53 
from HDM2-mediated degradation (Weber et al., 2000b; Weber et al., 1999; Zhang and 
Xiong, 1999). However, the nucleolar relocalisation of HDM2 does not appear to be 
required for p53 activation (Korgaonkar et al., 2002) and the redistribution of ARF into 
the nucleoplasm enhances its interaction with HDM2 and its p53-dependent growth-
suppressive activity (Korgaonkar et al., 2005). This current model of ARF function 
supports the concept that nucleolar disruption contributes to p53 signalling (Rubbi and 
Milner, 2003) since many stress signals perturb the nucleolus, causing the release of 
nucleolar proteins such as ARF, L11, L23, L5 and NPM, that activate the p53 pathway. 
 
It is less certain whether ARF can disrupt direct HDM2 inhibition of p53 transcription. 
ARF binds the central part of HDM2 (amino acids 210-304), which does not overlap 
with the N-terminal p53 binding domain of HDM2 (Bothner et al., 2001). This suggests 
that ARF may not prevent p53 binding to HDM2 by steric hindrance, and 
p53/HDM2/ARF ternary complexes are observed in vivo, with HDM2 acting as a bridge 
(Kamijo et al., 1998). These ternary complexes may somehow enhance p53 
transcription, as ARF can increase transcription from p53 reporter promoters without 
increasing p53 levels (Kamijo et al., 1998; Korgaonkar et al., 2002). 
 
In addition to HDM2, ARF-BP1 is a key regulator of the p53 cell cycle regulatory 
pathway; ARF-BP1 directly binds and ubiquitinates p53 in an HDM2-independent 
manner (Chen et al., 2005a). Silencing of ARF-BP1 expression in p53-positive cells 
extended the half-life of p53, resulted in the transcriptional activation of the p53 targets 
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p21Waf1 and Bax, and activated a p53-dependent apoptotic response (Chen et al., 
2005a). Unexpectedly, ARF-BP1 ubiquitinates and promotes the degradation of the 
anti-apoptotic Bcl-2 family member, Mcl-1, and down-regulation of ARF-BP1 
expression can also render cells more resistant to killing by genotoxic agents (Zhong et 
al., 2005). Thus, ARF-BP1 has been assigned both anti-apoptotic (via p53 degradation) 
and pro-apoptotic (via Mcl-1 degradation) functions. The divergent roles of ARF-BP1 
may be regulated by ARF. Following aberrant oncogene activation, ARF expression is 
induced and inhibits ARF-BP1 activity toward p53 in the nucleus, thereby leading to 
p53-dependent apoptosis. In the cytoplasm, where ARF is not abundant, oncogene 
activation may lead to ARF-BP1 mediated Mcl-1 degradation, further promoting 
apoptosis.  
 
1.2.5 Structure of ARF 
Human and mouse ARF proteins are arginine-rich, hydrophobic proteins of 132 and 169 
amino acids, respectively (Figure 1.4). They display no homology to other known 
human proteins and are poorly conserved, sharing only 50% amino acid identity (Stott 
et al., 1998). Exon 1ß shows lower homology between human and mouse proteins (45% 
identity) than exon 2 (57% identity) and, rather inexplicably for tumour suppressors, 
both ARF and INK4a sequences seem to be evolving rapidly and divergently at about 
three times the rate of other genes, including other members of the p53 and Rb tumour 
suppression network (Szklarczyk et al., 2007). 
 
Despite overall low homology, human and mouse ARF proteins show significant 
sequence similarity within their amino-terminal 14 amino acids (11/14 identity; see 
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Figure 1.4), and this region contains many of the known ARF functions, including 
nucleolar localisation, HDM2 binding and ability to induce cell cycle arrest. 
Furthermore, in chickens, only exon 1ß is translated to encode a smaller but functional 
7kDa ARF protein (Kim et al., 2003). Thus, it has been suggested that the INK4a/ARF 
exon-2 and -3 sequences simply act to stabilise the exon 1ß transcript (Sherr, 2006). 
However, the region encoded by the human INK4a/ARF exon 2 contains a second 
nucleolar localisation domain important for full HDM2 inhibition (Zhang and Xiong, 
1999). Additionally, many mammals translate the region of ARF encoded by exon 2 
(Szklarczyk et al., 2007), even though a simulation of a million possible exon 2 
sequence variants which did not alter the p16INK4a amino acid sequence showed only 4% 
of simulated sequences encoded full-length ARF (Szklarczyk et al., 2007). Taken 
together, these data suggest that the exon 2-encoded segment of ARF is functionally 
important.  
 
Figure 1.4 Comparison of the human, pig, rat, mouse and chicken ARF amino acid 
sequences 
Identical residues highlighted in black and conserved substitutions in grey. Functional motifs, including 
nucleolar localisation sequences (NoLS) of human and mouse sequences are also marked.  
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Nucleolar localisation of ARF is mediated by one nucleolar localisation sequence 
(NoLS) in murine p19ARF (residues 26-37) and by two NoLS in human p14ARF (2-14 
and 82-101) (Rizos et al., 2000; Weber et al., 2000b; Zhang and Xiong, 1999). These 
highly basic NoLS regions direct ARF to the granular compartment of the nucleolus 
(Bertwistle et al., 2004; Itahana et al., 2003; Lindstrom et al., 2000). 
 
Two arginine-rich sequences in the amino-terminus (aa 3-10 and 21-29) mediate 
binding to HDM2 (Bothner et al., 2001; Clark et al., 2002). These basic sequences 
interact electrostatically with the acidic residues (32%Asp/Glu) in the central region of 
HDM2 (amino acids 210-304) (Bothner et al., 2001). In solution, the N-terminus of 
p14ARF becomes organised upon binding to the central section of HDM2 and forms 
two ß-strands. The HDM2 protein forms ß-strands at residues 245-253 and 275-282 
upon binding to ARF (DiGiammarino et al., 2001), revealing a cryptic nucleolar 
localisation sequence in the RING finger domain of HDM2 (Lohrum et al., 2000). 
 
1.2.6 Expression in normal tissue 
The ARF promoter is a TATA-less CpG island that is characteristic of housekeeper 
genes (Robertson and Jones, 1998). It contains many Sp1 and E2F transcription factor 
binding sites. Low levels of p19ARF are expressed in many mouse tissues and levels 
increase in murine embryonic fibroblasts (MEFs) as they near senescence (Quelle et al., 
1995; Zindy et al., 1998). Murine p19ARF is transcriptionally upregulated by Ras and 
p19ARF-null MEFs are refractory to growth arrest induced by Ras (Serrano et al., 
1997). In contrast, human p14ARF expression levels remain low as cells near 
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senescence. Further, ARF transcription is not induced by Ras (Brookes et al., 2002; Wei 
et al., 2001) and p14ARF-deficient fibroblasts still undergo arrest in response to Ras 
(Lindstrom et al., 2000; Voorhoeve and Agami, 2003; Wei et al., 2001). 
 
Consistent with its role as a tumour suppressor, p19ARF is transcriptionally induced by 
a number of oncogenes, including E1A (de Stanchina et al., 1998), E2F1(Bates et al., 
1998; Elliott et al., 2001), E2F2/E2F3 (Berkovich et al., 2003), c-myc (Zindy et al., 
1998), Ras (Palmero et al., 1998),v-Abl (Radfar et al., 1998), ß-catenin (Damalas et al., 
2001) and the Dentin matrix protein 1 tumour suppressor (Inoue et al., 1999; 
Sreeramaneni et al., 2005). In addition, several inhibitors of senescence (e.g. bmi-1, B-
cell lymphoma 6 protein, chromobox 7, T-box 2, T-box 3) are known to repress the 
transcription of murine ARF (Brummelkamp et al., 2001; Gil et al., 2004; Jacobs et al., 
1999; Jacobs et al., 2000). Much less is known about the regulation of p14ARF 
expression; p14ARF transcription is induced by E2F1 (Parisi et al., 2002a), but not by 
oncogenic Ras alone. However, oncogenic Ras can cooperate with E2F1 to increase 
p14ARF transcription, and there is also some evidence that ß-catenin can induce ARF 
expression (Berkovich et al., 2003; Damalas et al., 2001). While p14ARF transcription 
is inhibited by T-box 2, T-box 3 and chromobox 7, it is not down-regulated by bmi-1 
(Bernard et al., 2005; Brummelkamp et al., 2001; Gil et al., 2004; Lingbeek et al., 
2002). Additionally, the oncogenic transcription factors Twist and AML-ETO repress 
transcription of ARF (Linggi et al., 2002; Maestro et al., 1999). 
 
1.2.7 ARF Degradation 
ARF is a relatively stable protein, with half-life estimations ranging from approximately 
one to six hours (our unpublished observations support an estimate at the higher end of 
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this range) (Kuo et al., 2004; Rodway et al., 2004). p19ARF and p14ARF (both 
lysineless proteins) undergo amino-terminal ubiquitination and their degradation 
depends on the ubiquitin-proteosome pathway and may be enhanced by HDM2 
expression (Kuo et al., 2004). Stress induced nucleoplasmic redistribution of ARF 
destabilises the protein, and targeting of a p14ARF fragment encompassing amino acids 
2-29 to the nucleolus increased its half-life (Rodway et al., 2004). Consistent with these 
data, the association of ARF with nucleophosmin (a nucleolar endoribonuclease) 
restricts ARF to the nucleolus and stabilises ARF by blocking its ubiquitination 
(Colombo et al., 2005; Colombo et al., 2006; Korgaonkar et al., 2005). In contrast, 
HDM2-ARF complex formation occurs preferentially in the nucleoplasm and this may 
allow for enhanced ARF ubiquitination and degradation (Korgaonkar et al., 2002).  
 
1.2.8 Nucleolar functions of the ARF tumour suppressor  
ARF is predominantly a nucleolar protein and rather than residing in inactive “storage” 
within the nucleolus (Korgaonkar et al., 2002; Rodway et al., 2004), ARF may regulate 
ribosome biogenesis by retarding the processing of early 47S/45S and 32S rRNA 
precursors (Sugimoto et al., 2003). These effects do not depend on HDM2 or p53 but 
may involve the interaction of ARF with nucleophosmin (NPM/B23). NPM is an 
abundant nucleolar endoribonuclease that is required for the maturation of 28S rRNA 
and interacts with many cellular proteins, including p53, HDM2, ARF and the BRCA1 
associated RING domain 1/breast cancer-1 ubiquitin ligase. The interaction of ARF and 
nucleophosmin retains both proteins in the nucleolus, bound to the pre-60S ribosome 
(Rizos et al., 2006), where they reduce ribosome biogenesis and nucleolar size, and as a 
result, protein synthesis and cell volume (Apicelli et al., 2008). The actual role of the 
nucleolar ARF-NPM complex remains unclear; data demonstrating that p19ARF 
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promoted the degradation of NPM (Itahana et al., 2003) are not supported by our 
findings with p14ARF (Rizos et al., 2006) nor indeed by other studies (Brady et al., 
2004; Korgaonkar et al., 2002). In response to cytotoxic drugs (such as actinomycin D) 
and DNA damaging agents (including UV light), NPM and ARF undergo 
nucleoplasmic redistribution, where HDM2 and NPM compete for ARF binding (Lee et 
al., 2005). The nucleoplasmic translocation of ARF and NPM promotes the formation 
of the ARF-HDM2 and the NPM-HDM2 binary complexes and induces potent 
activation of the p53 pathway (Lee et al., 2005). Thus, cell growth may be affected by 
ARF localised in either the nucleolus, via its association with NPM and ribosomes, or in 
the nucleoplasm, by its interaction with HDM2 and ARF-BP1. 
1.2.9 Other ARF binding partners 
ARF can also suppress the proliferation of mouse cells lacking both MDM2 and p53, 
implying interactions with other regulators. Consistent with these findings, the tumour 
susceptibility of knock-out mice lacking ARF and p53, with or without MDM2, is 
significantly greater than that associated with animals lacking either gene alone (Weber 
et al., 2000a). In searching for ARF binding proteins that are likely to underlie the p53-
independent effects of ARF, many other ARF-interacting proteins have been identified 
(see Table 1.5). However, the biological significance of these ARF-interactions on the 
tumour suppressor functions of ARF has not been well established. Most of these 
targets have been identified from yeast-2-hybrid screens and co-immunoprecipitation 
experiments involving over-expression of ARF. Determining the significance of these 
interactions is difficult as ARF is a highly basic protein with an isoelectric point of over 
12, making it notoriously “sticky”. In fact, only ARF’s interaction with HDM2 and 
perhaps with ARF-BP1 and nucleophosmin, has been shown to be relevant for its 
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tumour suppressing function (Chen et al., 2005a; Colombo et al., 2005; Pomerantz et 
al., 1998). 
 
Table 1.5 Cellular protein partners of the ARF tumour suppressor protein. 
ARF binding partner Biological Effect of ARF binding References 
ANCO1 Restrict nuclear receptor transcriptional activity (Tompkins et al., 2006) 
APA-1 No apparent effects (Benanti et al., 2002) 
ARF-BP1/Mule1 Inhibition of ARF-BP1 ubiquitin ligase activity (Chen et al., 2005a) 
ATR ATR/Chk1 activation and p53 phosphorylation (Rocha et al., 2005a) 
BCL6 Inhibition of BCL6 transcriptional activity (Shvarts et al., 2002) 
CARF Enhanced ARF-mediated cell cycle arrest (Hasan et al., 2002) 
CTBP1 Degradation of CtBP1 and apoptosis (Paliwal et al., 2006) 
c-MYC Inhibition of c-MYC transcriptional activity (Qi et al., 2004) 
DP-1 Inhibition of ARF-induced E2F proteolysis (Datta et al., 2005) 
E2F-1, -2, -3 Degradation of E2F (Eymin et al., 2001) 
Foxm1b Inhibition of Foxm1b transcriptional activity (Kalinichenko et al., 2004) 
GSPT1 Effect on activity of GST binding protein unknown (Tompkins et al., 2006) 
HIF-1α Inhibition of HIF-1α transactivation (Fatyol and Szalay, 2001) 
LZAP Suppresses of ARF inhibition of HDM2 (Wang et al., 2006) 
Mdm2 Inhibition of mdm2 ubiquitin ligase activity (Pomerantz et al., 1998) 
MdmX Enhanced p53 transactivation (Jackson et al., 2001) 
Neurabin Enhanced ARF-mediated cell cycle arrest (Vivo et al., 2001) 
Nucleophosmin Degradation of NPM, inhibition of NPM shuttling (Bertwistle et al., 2004) 
p120E4F Enhanced ARF-mediated cell cycle arrest (Rizos et al., 2003) 
p63 Inhibition of p63 transcriptional activity (Calabro et al., 2004) 
PARF Enhanced ARF signalling (Tompkins et al., 2006) 
Peroxin 19p Inhibition of p19ARF, does not bind human ARF (Sugihara et al., 2001) 
Tat-binding protein-1 Induces ARF stabilization (Pollice et al., 2004) 
Tip60 CHK2 phosphoylation and G2 arrest (Eymin et al., 2006b) 
Topoisomerase I Enhanced topoisomerase I activity (Karayan et al., 2001) 
Ubc9 Involvement in p14ARF-mediated sumoylation (Rizos et al., 2005) 
Werners helicase Nucleolar exclusion of Werners helicase (Woods et al., 2004) 
YY1 Decreased YY1/HDM2 binding (Sui et al., 2004) 
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1.2.10 ARF promotes the sumoylation of its binding partners 
p14ARF has recently been shown to promote the sumoylation of some of its binding 
partners, including HDM2 and nucleophosmin (Rizos et al., 2005; Tago et al., 2005; 
Xirodimas et al., 2002). Sumoylation is analogous to ubiquitination, and is the process 
by which the SUMO protein is conjugated to a target protein. The effects of this 
modification are target specific and include control of protein stability, formation of 
subnuclear structures and regulation of transcription factor activities (Melchior, 2000). 
The diverse functional consequences of sumoylation provide a possible explanation for 
the versatility of p14ARF downstream effects. Although ARF can promote sumoylation 
in vivo, the biological impact of target sumoylation has not been demonstrated for ARF 
binding partners, nor has any ARF-targeted sumoylation site been identified. Although 
the biological significance of ARF-mediated sumoylation remains to be established, the 
fact that a subset of melanoma-associated p14ARF mutations failed to sumoylate 
HDM2 in vivo (Rizos et al., 2005), suggests that sumoylation may provide a mechanism 
for the diverse actions of the ARF tumour suppressor proteins.  
 
1.2.11 Tumour suppressor functions – in vivo mice work 
The overlapping design of the INK4a/ARF locus has made it difficult to tease apart the 
relative contribution of ARF and p16INK4a. Mouse models have assisted in answering 
this question (Table 1.6). Initial mouse models knocked out exon 2 and thus disabled 
both p19ARF and p16INK4a. These INK4a/ARF-null mice were highly tumour-prone, but 
did not develop spontaneous melanomas and derivative cells exhibited an immortalised 
phenotype (Serrano et al., 1996). Disruption of exon 1ß in the mouse germline was 
subsequently used to generate mice lacking only p19ARF. Despite the fact that these 
animals continued to express wild-type p16INK4a, they exhibited a similar cancer-prone 
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phenotype to the INK4a/ARF-null mice (Kamijo et al., 1997). In contrast, the p16INK4a-
null mice were not especially tumour prone (~20% developed tumours by two years of 
age, mainly B-cell lymphomas); however these animals were susceptible to spontaneous 
melanoma development, albeit at a very low frequency (Krimpenfort et al., 2001; 
Sharpless et al., 2001). Intriguingly, when the INK4a/ARF–null mice were crossed with 
ARF hemizygotes, the animals developed melanomas and the penetrance rose from 8% 
to 50% after treatment with the carcinogen DMBA (Krimpenfort et al., 2001). The 
effect of ARF haploinsufficiency in the INK4a-null background suggests that the INK4a 
and ARF pathways cooperate in melanoma development. Similarly, INK4a/ARF-null 
mice expressing melanocyte-specific oncogenic H-RAS (Tyr-RAS) developed 
melanoma spontaneously with high penetrance (Chin et al., 1997). The Ras oncogene 
also co-operated with both ARF-null and p16INK4a-null mouse models to promote 
spontaneous melanoma (Sharpless et al., 2003). While Tyr-RAS mice are not tumour 
prone, 50% of Tyr-RAS/ARF-/- mice develop melanoma (40 week latency) and 35% of 
Tyr-RAS/INK4a-/- mice develop melanoma (75 week latency) (Sharpless et al., 2003). 
In summary, both products of the INK4a/ARF locus are involved in mouse melanoma 
development. 
 
The close functional connection between ARF and the p53 pathway is supported by the 
observation that p53-/-, p53/ARF-/- and p53/ARF/MDM2-/- (triple knockout; TKO) mice 
develop cancer with a similar latency (Kamijo et al., 1999; Moore et al., 2003; Weber et 
al., 2000a). Consistent with the role of ARF in activating the p53 pathway, tumours 
from ARF-null mice often retain p53 (Kamijo et al., 1997). Tumours from ARF-null 
mice have a wider spectrum than p53 null mice, demonstrating that the longer latency 
of ARF-null mice alters the tumour spectrum (Table 1.6).  
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Given the large number of binding partners that have been reported for ARF, it has been 
proposed that p14ARF may possess p53-independent tumour suppressor activity. 
Certainly, inactivation of p19ARF in p53-/- and p53/MDM2-/- mice expands the range 
and frequency of tumour (Weber et al., 2000a). However these results are not 
straightforward, as the interbred ARF-null and MDM2/p53 double knock out mice were 
all of mixed 129 X C57BL/6 background, and strain specific differences may have 
affected the result. The majority of the current data suggest that most functions of ARF 
action require intact p53.  
 
Table 1.6 Tumour spectrum and latency in different strains of ARF deficient mice.  
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References 
p19ARF-/- 62 0 33 39 17 9 0 
p16INK4a -/- 76 12 18 41 29 0 0 
INK4a/ARF-/- 38 0 90 0 10 0 0 
ARF+/-/INK4a-/- 
FVB 
 
52 9 18 45 27 0 0 
(Krimpenfort et al., 2001; 
Sharpless et al., 2001; 
Sharpless et al., 2004) 
          
p19ARF-/- 38 0 29 43 17 11 0 
p53-/- 16 0 70 30 0 0 0 
p19ARF/p53-/- 16 0 72 6 11 6 6 
p19ARF/p53/MDM2-/- 
C57BL/6 
x 129Sv 
16 0 68 26 0 5  
(Kamijo et al., 1999; 
Moore et al., 2003; Weber 
et al., 2000a) 
          
Tyr-Ras1  0 0 0 0 0 0 
Tyr-Ras1 p19ARF-/- 40 52 19 10  5 14 
Tyr-Ras1 p16INK4a-/- 75 35 6 0 6 0 53 
Tyr-Ras1 INK4a/ARF-/- 
C57BL/6 
x CBA x 
129Sv 
24 88  12    
(Chin et al., 1997; 
Sharpless et al., 2003) 
1Tyr-Ras mice express oncogenic Ras driven by the melanocyte specific tyrosinase promoter.  
 
1.2.12 smARF 
Interestingly, ARF mRNA also encodes a shorter, mitochondrial ARF (smARF) protein 
(Reef et al., 2006). smARF is produced in both the human and mouse as a result of 
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internal initiation of translation at Met45 in p19ARF and Met48 in p14ARF. It is a 
short-lived protein, with a half-life of under 1 h and accounts for only 1-5% of total 
ARF protein in the cell. Lacking the N-terminal nucleolar localisation signal of full 
length ARF, smARF localises to an internal mitochondrial compartment where it 
interacts with, and is stabilised by, the mitochondrial protein, p32 (Reef et al., 2007). 
Accumulation of smARF reduces mitochondrial membrane potential and induces 
autophagy and eventual cell death. The mitochondrial depolarisation induced by 
smARF does not lead to the leakage of mitochondrial products into the cytoplasm, nor 
is it inhibited by over-expression of anti-apoptotic Bcl-2 or Bcl-xL or dependent on p53, 
Bax, Bak or caspases. This demonstrates that smARF induced cell death is not an 
apoptotic process. Instead, smARF appears to alter the potential across the inner 
mitochondrial membrane, leading to loss of mitochondrial function. Cell death by 
autophagy ensues after 72 hours, presumably as a result of the energy crisis caused by 
mitochondrial dysfunction (Reef et al., 2007). The existence of smARF provides a 
possible explanation for p53-independent growth retardation observed by expression of 
full length ARF mRNA. However, because smARF production is so low, most data 
regarding smARF function relies on ectopically over-expressed smARF and thus the 
role of endogenous smARF in tumour suppression is yet to be defined. 
 
1.3 Apoptosis 
Although cell death has been the subject of research for over a century, the field of 
apoptosis was launched in earnest by a seminal article by Kerr describing common 
morphological features of cells undergoing programmed cell death (Kerr et al., 1972). 
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Kerr’s article coined the term “apoptosis” derived from the Greek “from falling”, a term 
used over 2000 years ago to describe leaves and petals falling from plants. 
 
Apoptosis is an essential process used to remove unwanted cells during development 
and to cull damaged, infected or potentially cancerous cells to prevent progression of 
disease or pathology. Apoptosis is a deliberate and active process, mediated by a 
network of proteins (Figure 1.5). As expected for a program that leads to cell death, 
there are many checks and balances. The central players in apoptosis are caspases 
(cysteine aspartyl proteases), proteases containing cysteine in their proteolytic domain 
which cleave their target at an aspartic acid residue (Stennicke and Salvesen, 1999). 
Caspases are expressed as an inactive pro-caspase that must be cleaved to become 
active. The caspase cascade begins with cleavage of the initiator caspases (including 
caspase 2, 8, 9, 10), which then cleave and activate downstream effector caspases 
(caspase 3, 6 and 7). Effector caspases 3, 6 and 7 cleave substrates such as the inhibitor 
of caspase-activated DNase (iCAD), lamin and poly(ADP-ribose) polymerase (PARP), 
leading to the phenotypic changes characteristic of apoptosis. These changes include 
chromatin condensation, exposure of phosphatidyl-serine to the exterior cytoplasmic 
membrane and DNA fragmentation (Clarke, 1990; Enari et al., 1998; Fadok et al., 
1992; Ruchaud et al., 2002; Sakahira et al., 1998; Tewari et al., 1995). The cascade of 
events that cause apoptosis allow for signal amplification, and once activated provide a 
surge of pro-apoptotic signalling that ensures cell death. The cascade also provides an 
opportunity for many checkpoints to control this potentially dangerous cellular 
program. 
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Figure 1.5 Overview of apoptosis pathways 
Anti-apoptotic Bcl-2 family members are in green text. Pro-apoptotic Bcl-2 family proteins and 
mitochondrial proteins are in red text (see text for details). DD; death domain. 
 
 
 
1.3.1 The extrinsic apoptotic pathway 
Initiating apoptotic signals may come from either membrane bound death receptors (the 
extrinsic pathway) or via the mitochondria (the intrinsic pathway). At the apex of the 
extrinsic pathway is the TNF (tumour necrosis factor) receptor superfamily which 
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includes death receptors such as fibroblast-associated receptor (Fas/Apo1/CD95), 
tumour necrosis factor receptor (TNFR1/2) and TNF-related apoptosis inducing ligand 
receptor (TRAIL-R1/TRAIL-R2/DR5) (Wajant, 2003; Wajant et al., 2005). Binding of 
the respective ligands (FasL, TNF- α and TRAIL) to their receptors results in receptor 
trimerisation and leads to the formation of the death inducing signalling complex 
(DISC) (Kischkel et al., 1995). During DISC formation, the cytoplasmic death domain 
(DD) containing region of the receptor recruits Fas-associated DD containing protein, 
which in turn recruits caspase 8. The high local concentration of caspase 8 at the DISC 
increases its auto-proteolytic capacity by 100 fold, resulting in self-cleavage and 
activation of caspase 8 (Medema et al., 1997; Muzio et al., 1998). Caspase 10 can also 
be recruited to, and activated by, the DISC complex, but its role in initiating apoptosis 
has not been fully elucidated (Kischkel et al., 2001).  
 
The activity of the DISC, and therefore caspase 8 activation, can be inhibited by FLICE 
inhibitory protein (cFLIP) (Irmler et al., 1997). cFLIP is highly expressed in 83% of 
melanomas, providing resistance to TRAIL mediated apoptosis (Bullani et al., 2001; 
Chawla-Sarkar et al., 2004). Additionally cFLIP expression is induced by nuclear factor 
kappa B (NF-κB) in a cell specific manner (for example, it is induced by NF-κB in 
transformed murine fibroblast SV40 and human breast cancer MCF-7 cells, but not in 
human embryonic kidney HEK293 or Jurkat T-cells), and is one way that NF-κB 
mediates cell protection from apoptosis (Kreuz et al., 2001). p14ARF accumulation can 
inhibit NF-κB, thereby increasing the sensitivity of some cell types to extrinsic pathway 
activation (Rocha et al., 2005a). 
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Cells can be classified as type I or type II depending on the potency of their activated 
caspase 8 response. In Type I cells, active caspase 8 cleaves effector caspases, leading 
to apoptosis directly (Martin and Fearnhead, 2002; Scaffidi et al., 1998). In type II cells, 
activation of effector caspases by caspase 8 is insufficient to directly cause apoptosis. In 
this case, caspase 8 may cleave the Bcl-2 family member Bid, which in its truncated 
form (tBid) causes mitochondrial depolarisation, thereby linking the extrinsic and 
intrinsic pathways (Figure 1.5) (Ozoren et al., 2000). 
 
1.3.2 The intrinsic apoptotic pathway 
The mitochondria are central to the intrinsic apoptotic pathway. Programmed cell death 
is induced by changes in mitochondrial permeability and the release of mitochondrial 
proteins such as cytochrome c, apoptosis inducing factor (AIF), endonuclease G and 
second mitochondria-derived activator of caspases/direct IAP binding protein with low 
pI (SMAC/DIABLO) via pores in the outer mitochondrial membrane (Figure 1.5). Once 
cytochrome c is released into the cytoplasm, it binds to apoptotic protease activating 
factor 1 (APAF-1) and, with the co-activator ATP, recruits caspase 9 to its caspase 
recruiting domain, leading to caspase 9 activation (Riedl et al., 2005; Yu et al., 2005). 
Caspase 9 can then cleave and activate down-stream effector caspases 3 and 7 (Li et al., 
1997; Twiddy et al., 2006), with caspase 6 then being activated by caspase 3 (Slee et 
al., 1999). Caspase 9 activation can also positively regulate its own activation by 
cleaving targets that lie upstream of mitochondrial depolarisation. These including Bid, 
caspase 2 and caspase 8, thereby promoting further mitochondrial depolarisation and 
reinforcing the apoptotic signal (Henderson et al., 2003; Samraj et al., 2007). As a 
result, once initiated, all mitochondria in a cell depolarise rapidly and completely 
(Goldstein et al., 2000).  
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Pore formation in the outer mitochondrial membrane is facilitated by the concerted 
action of members of the Bcl-2 family. Members of this family contain up to four Bcl-2 
homology domains (BH1-BH4) that mediate interaction with other members of the 
family. The Bcl-2 superfamily contains both pro- and anti-apoptotic members and can 
be divided into three groups. The first group are anti-apoptotic members that contain all 
four homology regions, including B-cell lymphoma 2 (Bcl-2), Bcl-xL, myeloid cell 
leukemia sequence 1 (Mcl-1), Bcl-2-related protein A1 (A1) and Bcl-w (Boise et al., 
1993; Gibson et al., 1996; Kozopas et al., 1993; Lin et al., 1993; Vaux et al., 1988). 
The second group comprises of the pro-apoptotic members Bcl-2-associated X protein 
(Bax) and Bcl-2 antagonist killer 1 (Bak) which contain BH domains 1-3 (Farrow et al., 
1995; Oltvai et al., 1993). The last group are pro-apoptotic members that only contain 
the BH3 domain and are termed BH3-only proteins. This sub-set of the Bcl-2 family 
includes Bcl-2-interacting domain (Bid), Bcl-xL/Bcl-2-associated death promoter (Bad), 
Bcl-2 interacting mediator of cell death (Bim), PMA-induced protein (Noxa) and p53-
upregulated modulator of apoptosis (PUMA) (Nakano and Vousden, 2001; O'Connor et 
al., 1998; Oda et al., 2000; Wang et al., 1996; Yang and al, 1996). While there is debate 
regarding the dynamics of Bcl-2 family member activation, the prevailing model posits 
that activated Bax and Bak can oligomerise and form pores in the mitochondrial outer 
membrane, but are inactivated by the anti-apoptotic Bcl-2 members. BH3-only pro-
apoptotic proteins alleviate this inhibition by binding with anti-apoptotic Bcl-2 
members, facilitating the assembly of Bax and Bak into pores in the outer mitochondrial 
membrane (Figure 1.5) (Willis et al., 2007). 
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Preventing Bax and Bak activation are the anti-apoptotic members of the Bcl-2 family: 
Bcl-2; Bcl-xL; Mcl-1; A1 and Bcl-w. These proteins bind to Bax and Bak, sequestering 
them into inactive dimers that are unable to oligomerise (Cheng et al., 2001; Ross et al., 
2001; Ruffolo and Shore, 2003; Youle and Strasser, 2008). The BH1, 2 and 3 domains 
of the anti-apoptotic Bcl-2 proteins form a hydrophobic pocket that binds to the BH3 
domain of Bax and Bak (Lalier et al., 2007). High expression of anti-apoptotic Bcl-2 
members confers a survival advantage to cells, and melanomas often express high levels 
of Bcl-2, Bcl-xL and Mcl-1 (Table 1.2). Bcl-2 expression is essential for developing 
melanocytes, and Bcl-2-/- mice are deficient in melanocytes, and lose pigmentation after 
birth (McGill et al., 2002; Yamamura et al., 1996). The Bcl-xL and Mcl-1 genes are 
essential for normal embryogenesis and mice deficient either of these genes die before 
implantation or shortly after birth (Motoyama et al., 1995; Rinkenberger et al., 2000). 
 
The pro-apoptotic BH3-only proteins bind and inhibit the anti-apoptotic Bcl-2 family 
members, thereby relaying apoptotic signals to the mitochondria (Uren et al., 2007). As 
a result, the induction of BH-3 only proteins (which include Bid, Bad, Bim, Noxa, and 
PUMA), facilitate the oligomerisation of Bax and Bak and apoptosis. 
 
In what has been called the “Bax/Bak rheostat model”, the balance between opposing 
pro- and anti-apoptotic Bcl-2 proteins determines cell fate (Korsmeyer et al., 1993). The 
various Bcl-2 members are regulated at transcriptional and post-translational levels. 
Cell stress can increase the level of Bax, Bid, PUMA and NOXA by p53-mediated 
transcriptional activation (Miyashita and Reed, 1995; Nakano and Vousden, 2001; Oda 
et al., 2000; Sax et al., 2002; Yu et al., 2003). While Bid is a transcriptional target of 
p53, it is an inactive zymogen that is mainly regulated by activating cleavage by 
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caspase 8 or cathepsins (Garnett et al., 2007; Li et al., 1998; Stoka et al., 2001). 
Additionally, p53 binds and represses transcription from the Bcl-2 and Mcl-1 promoter 
(Pietrzak and Puzianowska-Kuznicka, 2008; Wu et al., 2001). Bcl-2 is also a target of 
microphthalmia associated transcription factor (MITF), a master regulator in 
melanocytes that controls the growth and differentiation of melanocytes (Lekmine et 
al., 2007), and MITF loss in melanocytes causes apoptosis that can be rescued by Bcl-2 
over-expression (McGill et al., 2002). Mcl-1 can also be poly-ubiquitinated by ARF-
BP1, leading to its degradation by the 26S proteosome (Zhong et al., 2005). While 
p14ARF can inhibit the ability of ARF-BP1 to ubiquitinate p53, it is not certain if this 
function extends to ARF-BP1 degradation of Mcl-1. 
 
1.3.2.1 Specificity of Bcl-2 binding interactions 
Apoptosis is also regulated by the selective binding activity of the Bcl-2 family of 
proteins (Fletcher and Huang, 2008). Bim, PUMA and tBid, bind all anti-apoptotic Bcl-
2 members while Bad only binds Bcl-2, Bcl-xL and Bcl-w, and NOXA only binds Mcl-1 
and A1 (Figure 1.5) (van Delft and Huang, 2006; Willis et al., 2005; Youle and 
Strasser, 2008). Therefore, in cells expressing Bcl-2 and Mcl-1, over expression of Bad 
or Noxa alone will not lead to apoptosis, while they do kill when expressed together 
(Chen et al., 2005b). Additionally, the anti-apoptotic Bcl-2 members differ in their 
ability to inhibit Bax and Bak. Mcl-1 and Bcl-xL bind both Bak and Bax, while Bcl-2, 
Bcl-w and A1 bind Bak alone (Willis et al., 2005). Expression of the Bcl-2 members 
differs between cell types and tumours. Therefore, the BH-3 mimetic ABT-737, which 
acts like Bad to inhibit Bcl-2, Bcl-xL and Bcl-w, is unlikely to be effective as a single 
agent in melanomas, which often have high Mcl-1 expression levels (Adams et al., 
2005; Zhuang et al., 2007). 
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1.3.2.2 Other mitochondrial pro-death molecules 
As well as cytochrome c release, mitochondrial outer membrane permeabilisation also 
causes the release of other mitochondrial inter-membrane space proteins that contribute 
to cell death. These include SMAC/DIABLO, high temperature requirement protein A2 
(Omi/HtrA2), endonuclease G and apoptosis inducing factor (AIF). SMAC/DIABLO 
and Omi contribute to caspase dependent cell death by inactivating the function of the 
inhibitor of apoptosis proteins (IAPs). IAPs are negative regulators of activated 
caspases, that may prevent run-away caspase activation from auto-proteolysis. IAPs 
include X-linked inhibitor of apoptosis (XIAP), c-IAP1, c-IAP2, neuronal IAP and 
survivin (Deveraux and Reed, 1999; Liston et al., 1996; Roy et al., 1997; Uren et al., 
1996). They inhibit caspases 3, 7 and 9 directly and inhibit activation of caspase 8 by 
Fas (Deveraux et al., 1999; Deveraux et al., 1997; Takahashi et al., 1998). Melanomas 
frequently express high levels of survivin and XIAP which contribute to their apoptotic 
resistance and is associated with poor prognosis (Chawla-Sarkar et al., 2004; Gradilone 
et al., 2003; Grossman et al., 1999; Liu et al., 2006). 
 
Release of the AIF protein from mitochondria can cause caspase-independent cell death. 
Newly synthesised AIF is imported from the cytoplasm to the mitochondrial inter-
membrane space, where its mitochondrial localisation signal is cleaved to generate the 
mature protein. Over-expression or micro-injection of mature AIF leads to caspase 
independent peripheral chromatin shrinkage, phosphatidyl-serine exposure and cleavage 
of genomic DNA into high moleculare weight fragments (<50kbp) (Susin et al., 1999). 
Release of AIF from the mitochondria is required for its apoptotic activity, and it is not 
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inhibited by z-VAD-fmk, a pan-caspase inhibitor. AIF does not have any intrinsic 
nuclease activity itself, and its downstream effectors have not been elucidated (Daugas 
et al., 2000; Susin et al., 2000). Another potential mediator of cell death that may be 
released by mitochondrial outer membrane permeabilisation is endonuclease G, a 
DNase that causes caspase-independent, large-scale DNA fragmentation (Li et al., 
2001). The role of endonuclease G in promoting cell death in melanoma is uncertain; a 
variety of apoptotic stimuli promoted mitochondrial release of cytochrome c, 
SMAC/DIABLO, and AIF but not endonuclease G (Liu et al., 2006). Endonuclease G 
may be important to promoting death in cells with low caspase activity (van Gurp et al., 
2003). 
 
1.3.3 Caspase independent cell death 
Although caspase-driven apoptosis has been the main focus of cell death study in the 
past few decades, the contribution to disease of other programmed cell death pathways 
is now being recognised. Alternate death mechanisms may be mediated by autophagy, 
cathepsins and calpains. 
 
1.3.3.1 Autophagy 
An alternate pathway leading to cell death is autophagy (used here to refer to 
macroautophagy), a process that can be triggered by the ARF variant smARF (Reef et 
al., 2006). Autophagy is an self-cannibalisation process characterised by the formation 
of double membrane enclosed cytoplasmic vesicles that engulf cytoplasmic contents 
and organelles such as mitochondria and endoplasmic reticulum (for review see 
(Mizushima, 2007)). These vesicles (autophagosomes) deliver their contents to 
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lysosomes, where they are degraded and recycled. Autophagy was long viewed as a cell 
survival mechanism as it can provide cells with essential metabolic substrates in 
starvation conditions. However, it is now recognised that autophagy can also contribute 
to cell death (Clarke, 1990). Autophagy can cause cell death via the destruction of vital 
cellular components, leading to cellular dysfunction and atrophy (Gozuacik and Kimchi, 
2007). While autophagic death causes chromatin shrinkage, in contrast to caspase 
mediated death it does not result in DNA fragmentations or the formation of apoptotic 
bodies (Gozuacik and Kimchi, 2007). 
 
1.3.3.2 Calpain and Cathepsin proteases 
Calpains are cytosolic proteases that are activated by high Ca2+ levels and their 
activation can lead to cell death (Goll et al., 2003). Calpains do not have strict cleavage 
specificity, and cleave a number of proteins involved in apoptosis. Cleavage of Bcl-2 
and Bcl-xL by calpains can tip the balance of the Bcl-2 family towards apoptosis and 
cause mitochondrial depolarisation (Vandenabeele et al., 2005). Additionally, Bax is 
cleaved by calpains, forming an 18kDa product that potently induces apoptosis (Gao 
and Dou, 2000). Calpains also cleave caspases, but at different sites to upstream 
caspases, often resulting in caspase inactivation (Chua et al., 2000). Caspase 3 can also 
cleave and inactivate the negative calpain regulator calpastatin, to create a network 
between the caspase and calpain death pathways (Porn-Ares et al., 1998). 
 
Another class of proteases, cathepsins, can also mediate cell death. Cathepsins mainly 
reside in the lysosome, where they degrade and recycle lysosomal contents and process 
antigens for presentation to MHC class II receptors (Chwieralski et al., 2006). Like 
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calpains, cathepsins have less site specificity than the caspases, and if released into the 
cytoplasm by extensive lysosomal rupture they can cause massive protein degradation 
and necrosis (Bursch, 2001). However small amounts of released cathepsins can lead to 
apoptosis, probably via cleavage and activation of Bid, and degradation of anti-
apoptotic Bcl-2, Mcl-1 and Bcl-xL (Cirman et al., 2004; Stoka et al., 2001; Turk and 
Stoka, 2007).  
 
1.4 ARF and Apoptosis 
 
The role of p14ARF in the apoptotic pathway remains controversial. There are 
important differences between the murine and human ARF homologues, and conflicting 
observations in different cellular contexts. MEFs over-expressing p19ARF undergo cell 
cycle arrest (Quelle et al., 1995), but cells overexpressing p19ARF, together with E1A, 
Myc or RAS oncogenes undergo apoptosis (de Stanchina et al., 1998; Russell et al., 
2002; Zindy et al., 1998). Activation of murine ARF alone can also trigger apoptosis; 
the ectopic expression of p19ARF with a cre/loxP-regulated adenoviral vector induced 
apoptosis in p53-null MEFs, p53-intact human U2OS cells, and p53-deficient human 
SAOS-2 cells (Matsuoka et al., 2003; Suzuki et al., 2003; Tsuji et al., 2002).  
 
The C-terminal region of the murine ARF protein (amino acids 130-169) is important 
for p19ARF-mediated apoptosis, but this region is not conserved in human p14ARF 
(Matsuoka et al., 2003) (see Figure 1.4). Thus, p14ARF may not be as potent an 
apoptotic regulator as its murine counterpart; ectopic Myc expression did not induce 
extensive apoptosis in human diploid fibroblasts despite obvious upregulation of 
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p14ARF and p53 (Drayton et al., 2003). Additionally, long-term stable transient 
p14ARF expression did not lead to apoptosis in p53 intact lung cancer or glioma cells 
(Gao et al., 2001; Simon et al., 2006) or p53-null SAOS-2 (osteosarcoma) and H358 
(bronchioloalveolar carcinoma) cells (Eymin et al., 2001). Nor did p14ARF induction 
cause apoptosis in HT-1080 fibrosarcoma cells (p53 defective, with p14ARF expressed 
under the Tet-on promoter (Magro et al., 2004). 
 
Many groups have used adenoviral expression systems to investigate the functions of 
ARF. These studies show that p14ARF induces the death of p53-intact cells (Deng et 
al., 2002; Kim et al., 2004; Matsuoka et al., 2003; Yang et al., 2000; Yarbrough et al., 
2002) but not p53-null cells (Deng et al., 2002; Kim et al., 2004; Matsuoka et al., 2003; 
Yang et al., 2000; Yarbrough et al., 2002). In contrast, others have shown that p14ARF 
induces apoptosis independently of p53 (Hemmati et al., 2002). Knockout/knock-in 
models of HCT116 and DU145 colorectal cancer cells showed p14ARF caused 
apoptosis independent of p53 and Bax after 72 hours, and death occurred via 
mitochondrial depolarisation and was caspase dependent (Hemmati et al., 2002; 
Hemmati et al., 2006; Hemmati et al., 2005). Titrations of virus levels show that 
apoptosis increases with p14ARF expression levels (Deng et al., 2002; Hemmati et al., 
2002) and abnormally high expression levels may have contributed to the p53-
independent apoptosis observed by Hemmati et al (Hemmati et al., 2002). 
 
In some cases, extended p14ARF signalling is needed to cause apoptosis. In these cases 
over six days of p14ARF expression was required to cause apoptosis in a p53-
dependent (Sekaric et al., 2007) or independent (Eymin et al., 2003) manner. Long-term 
p14ARF expression can also lead to a senescent phenotype, with cells enlarging, 
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becoming vacuolated, and in some cases becoming ß-galactosidase positive (Sekaric et 
al., 2007; Shamanin and Androphy, 2004). 
 
ARF might reasonably be expected to cause apoptosis by up-regulating p53. p53 is a 
major apoptotic regulator and many of its transcriptional targets are pro-apoptotic, 
including Bax, Fas, p53-regulated apoptosis-inducing protein 1, PIDD, PUMA and 
NOXA (reviewed in (Das et al., 2008; Fridman and Lowe, 2003)). p53 also represses 
the pro-survival proteins survivin, Bcl-2 and Mcl-1 (Hoffman et al., 2002; Pietrzak and 
Puzianowska-Kuznicka, 2008; Wu et al., 2001). Both Bax and Fas have been reported 
to be key mediators of ARF induced apoptosis (Kim et al., 2004; Suzuki et al., 2003). 
Bax (but not Bak) is required for ectopic p19ARF killing of SV-40 transformed MEFs 
(Suzuki et al., 2003) and in human cells, apoptosis and chemosensitisation induced by 
adenovirally-expressed p14ARF is associated with increased Bax expression (Li et al., 
2006; Nakazawa et al., 2003; Yuan et al., 2007). Bax is not always required for 
adenovirally-expressed p14ARF-induced apoptosis; in HCT116 cells Bak can 
functionally replace Bax, and loss of both abrogates apoptosis caused by adenovirus-
mediated p14ARF over-expression (Hemmati et al., 2006). Expression levels of the 
different Bcl-2 family members could explain differences between Bax and Bak 
requirement in specific cell types. Anti-apoptotic members of the Bcl-2 family (Bcl-2, 
Bcl-xL, Mcl-1 among others) target Bax and Bak differentially; Bcl-xL/Mcl-1 inhibit 
Bak more potently than Bax, while Bcl-2, Bcl-w and A1 specifically inhibit Bax (Willis 
et al., 2005). Therefore, cells with high levels of Mcl-1 and/or Bcl-xL that effectively 
disables Bak would be dependent on Bax activity for intrinsic pathway activation. 
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In many cases p53 stabilisation does not lead to apoptosis, but rather promotes cell 
cycle arrest (Draus et al., 2001; Soddu et al., 1996). p53-mediated transcription of pro-
arrest targets can also inhibit apoptosis. Stabilisation of p53 by ARF results in increased 
p21Waf1 – a direct target of p53 that inhibits cell cycle progression by binding 
CDK/cyclin complexes. p21Waf1 can inhibit apoptosis by inhibition of cyclin-dependent 
kinase-mediated caspase-9 activation (Sohn et al., 2006), inhibition of death receptor 
activation of caspase 8 and 10 (Xu and El-Deiry, 2000), and binding to caspase 3 
(Suzuki et al., 2000; Suzuki et al., 1998). Additionally, loss of p21Waf1 increases 
apoptosis in response to cytotoxic agents (Wendt et al., 2006) and ARF over-expression 
(Hemmati et al., 2005).  
 
1.4.1 Post-translational modification of p53 by ARF 
The transcriptional spectrum of p53 is altered by its many post-translational 
modifications. While ARF has not been reported to directly modify p53, ARF 
accumulation increases sumoylation of p53 by HDM2, with as yet undetermined effects 
(Chen and Chen, 2003). Additionally, p53 accumulated in response to ARF may be 
acetylated by the p53 co-activator and histone acyltransferase p300 (Mellert et al., 
2007; Sekaric et al., 2007). Acetylation of p53 at lysine 382 by p300 requires hADA3, 
and is inhibited by HDM2, thus ARF-mediated HDM2 inhibition favours p53 
acetylation (Sekaric et al., 2007; Wang et al., 2001a).  
 
1.4.2 ARF and chemosensitivity 
There have also been a few studies suggesting that p14ARF accumulation may 
influence chemosensitivity. In most cases, p14ARF only increased the chemosensitivity 
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of cells with functional p53. Adenoviral-mediated p14ARF over-expression sensitised 
MCF-7 breast cancer cells to cisplatin, but not to taxol (Deng et al., 2002) and stable 
p14ARF expression increased the radiosensitivity of p53-intact lung cancer (Gao et al., 
2001) and glioma cells (Simon et al., 2006). Although p14ARF expressing glioma cells 
were more radiosensitive, they were not rendered more sensitive to vincristine (an 
inhibitor of tubulin polymerisation) or the nitrosourea BCNU (Simon et al., 2006). 
Although p53 dependence is suggested by these three reports, it has not been 
conclusively demonstrated with the use of isogenic p53-null/knock-down cell lines. 
 
There is also evidence that p14ARF can modulate chemosensitivity in a p53 
independent manner. p14ARF expressed under the Tet-on system in p53-defective HT-
1080 fibrosarcoma cells decreased death induced by the antifolates methotrexate, 
trimetrexate and raltitrexed (Magro et al., 2004). This was found to be due to decreased 
dihydrofolate reductase levels and increased thymidine salvage; ARF binds DP1 
(DRTF1 polypeptide 1), a co-activator of E2F1, thereby reducing transcription of the 
E2F1 target, dihydrofolate reductase (Datta et al., 2002; Datta et al., 2005). ARF 
mediated inhibition and degradation of E2F1 may regulate the apoptotic program as 
E2F1 can cause apoptosis independent of p53 and E2F1 also represses the anti-
apoptotic Mcl-1 (Croxton et al., 2002; Elliott et al., 2001) 
 
1.4.2.1 ARF represses NF-κB via ATR 
ARF has also been shown to repress the transcriptional activity of the nuclear factor 
kappa B (NF-κB) subunit RelA (p65) (Rocha et al., 2003; Rocha et al., 2005a). 
p14ARF expression induced threonine-505 phosphorylation of RelA via a mechanism 
43 
dependent on telangiectasia mutated and Rad -3 related protein (ATR) and checkpoint 
kinase 1 (Chk1), leading to repression of anti-apoptotic targets such as Bcl-xL and, 
potentially, cFLIP, increasing sensitivity to TNF (Kreuz et al., 2001; Rocha et al., 
2005a). It is proposed that ARF activates ATR, leading to the phosphorylation of Chk1. 
Chk1 phosphorylation induced by ARF expression is low compared to UV radiation 
induced Chk1 phosphorylation, but is independent of p53 and HDM2. As NF-κB has 
many pro-survival targets, p14ARF repression of RelA could provide a pro-apoptotic 
stimuli in many settings. 
 
1.5 Scope of this thesis 
The ARF tumour suppressor monitors abnormal proliferative signals and initiates 
defensive mechanisms that either halt cell division or trigger cell death. Accordingly, 
the loss of ARF strongly predisposes to spontaneous cancer development in humans and 
in mice. The precise mechanisms of ARF action are critical to understanding the genesis 
and control of melanoma as well as many other human cancers. In this work we have 
focussed on dissecting the impact of the human p14ARF protein on the survival and 
chemosensitivity of human cells. 
